Granules India Limited has informed the Exchange about Transcript

Granules India reported FY24 revenue of INR 45,064 million, almost flat YoY, with Q4 FY24 revenue at INR 11,758 million (down 2% YoY). However, EBITDA margins improved sharply to 21.7% in Q4 (from 19.1% YoY) driven by a shift in product mix toward Finished Dosages (FD), which now contribute 65% of revenue versus 50% a year ago. Value-added as a percentage of sales rose to 55.1% in FY24 from 48.9% in FY23. Full-year EBITDA was INR 8,560 million (down 6% YoY) due to higher R&D spend (4.5% of sales). Management guided FY25 EBITDA margins of 22–23%, gross margin sustainability of 55–58%, and FD share rising toward 70% within a year. They plan 16–18 product launches in FY25, with capex of around INR 600 crore, and aim to keep net debt to EBITDA near 1.0–1.1 rather than aggressively reducing debt. The paracetamol API segment continues to face price erosion expected to last 2–3 more quarters.